Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2018-09-03 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于控股股东股权解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Kangzhi Pharmaceutical Co., Ltd. regarding the release of pledged shares by its controlling shareholder. It details the dates and amounts of shares pledged and subsequently released, along with references to previous announcements about the pledging. The document is short (920 characters) and focuses on share pledge status updates, which is a capital structure related disclosure. It does not contain financial statements, management discussion, or audit information. It is not a report or a presentation but an announcement about share capital changes related to pledge release. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2018-09-03 Chinese
关于现金收购中山爱护日用品有限公司100%股权暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 康芝药业股份有限公司 regarding the cash acquisition of 100% equity in 中山爱护日用品有限公司. It details the approval of the acquisition by the board and shareholders, the completion of the equity transfer, and the issuance of a new business license. The document includes specifics about the acquired company and references prior meeting resolutions and announcements. There is no financial statement or detailed financial analysis present, nor is this a report or transcript. It is an update on a capital transaction involving acquisition and related progress. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is short and focused on the acquisition progress, not a full report or regulatory filing.
2018-08-31 Chinese
广州证券股份有限公司关于深圳证券交易所《关于对康芝药业股份有限公司的问询函》（创业板问询函【2018】第346号）之核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion issued by Guangzhou Securities Co., Ltd. regarding an inquiry letter from the Shenzhen Stock Exchange about Kangzhi Pharmaceutical Co., Ltd. It extensively discusses the history of equity changes, capital increases, and share transfers related to Zhongshan Aihu, a subsidiary involved in a strategic acquisition by Kangzhi Pharmaceutical. The document includes audit reports, asset valuation reports, board and shareholder meeting resolutions, and detailed explanations of the transaction's fairness and compliance with regulatory requirements. It is a formal verification and audit opinion related to a regulatory inquiry, focusing on the legitimacy and rationale of the equity transactions and acquisition pricing. The document does not present itself as a full annual or interim financial report, earnings release, or investor presentation. It is not a simple announcement but a comprehensive audit and verification report responding to a regulatory inquiry. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Q1 2018
2018-08-28 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "康芝药业股份有限公司 2018 年半年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2018 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion, and analysis for the half-year period of 2018. The document includes sections such as company overview, financial indicators, business summary, risk factors, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data and analysis confirms it is an Interim / Quarterly Report (IR). H1 2018
2018-08-20 Chinese
独立董事关于第四届董事会第十七次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's 2018 semi-annual report and related issues such as external guarantees and use of raised funds. It references regulatory guidelines and provides an independent opinion on the half-year report and related financial matters. The document length is short (1182 characters) and it does not contain actual financial statements or detailed financial data, but rather an independent opinion or certification related to the interim report. This fits the profile of an Audit Report / Information (AR) as it is a standalone audit-related opinion on specific financial and regulatory compliance matters, not the full interim report itself. H1 2018
2018-08-20 Chinese
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2018 semi-annual report and a special report on the use of raised funds. It includes voting results and confirms the accuracy and completeness of the reports. The document is short (918 characters) and primarily announces the approval of the semi-annual report rather than containing the report itself. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to it. However, since it is a formal resolution announcement by the Supervisory Board about the semi-annual report and related matters, it fits best under Regulatory Filings (RNS) as it does not contain the full financial data or detailed analysis of the report but certifies and approves it.
2018-08-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.